TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04200170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rose
Description: Rose is a patient-centric, mobile mental health platform designed for in-between clinical mental health monitoring in form of mood tracking, clinical surveys and daily journaling. Rose is used as a participant-facing mobile app and clinician-facing dashboard. Each day, they complete mood and anxiety scales and update their journals. Biweekly, they are also asked to complete the PHQ-9 and GAD-7 assessments as well. The Rose mobile app sends timely self-help articles and notifications for users. The curated insights are selected based on participant responses to the daily mood and anxiety surveys, as well as a built-in sentiment analysis of the journaling. The clinical dashboard is a secure, web-based portal that has a unique login for each provider. Providers have access to only their patients through the system and are able to see all the health metrics collected with the Rose mobile app and the summarized metrics produced by our models.
Study: NCT02467907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks
Study: NCT02485743

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Diet Products
Description: A range of Active Diet Products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein, and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Diet Products
Description: A range of Placebo Diet Products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
Study: NCT01495195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose donepezil
Description: Donepezil titrated to 22.5 mg daily
Study: NCT06207019

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyflex EDM , The XP-endo Shaper, Primary WaveOne Gold
Description: rotary single files
Study: NCT01691898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pinatuzumab Vedotin
Description: Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
Study: NCT06207019

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyflex EDM , The XP-endo Shaper, Primary WaveOne Gold
Description: rotary single files

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyflex EDM , The XP-endo Shaper, Primary WaveOne Gold
Description: rotary single files
Study: NCT01691898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pinatuzumab Vedotin
Description: Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
Study: NCT01495195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose donepezil
Description: Donepezil titrated to 22.5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose donepezil
Description: Donepezil titrated to 10 mg daily
Study: NCT01691898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: RTX 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: RTX 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: RTX 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle.
Study: NCT03285984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
Description: Toothpaste containing 67 percent (%) Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride
Description: Toothpaste containing 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
Description: Whitening Toothpaste containing 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
Study: NCT01495195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline
Description: Transdermal selegiline, 6 mg daily
Study: NCT03285984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
Description: Toothpaste containing 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
Study: NCT00920634

Intervention type: DRUG
Intervention: Follitropin beta
Description: For subcutaneous or intramuscular injection, the usual dosage is 50 IU of follitropin beta (recombinant) once daily for 7 days. The dosage should be adjusted subsequently while monitoring the development of follicles (dose increase by 25 IU every 7 days if the response of the ovaries is poor) and, after confirming presence of follicles of 18 mm or larger in mean diameter by the ultrasonic tomography, ovulation is induced by the administration of a human chorionic gonadotropin preparation.
Study: NCT00413244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AndroGel 5 Grams
Description: Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
Study: NCT02019277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Dosing regimen to be determined by the investigator, routine clinical practices.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Dosing regimen to be determined by the investigator, routine clinical practices.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Dosing regimen to be determined by the investigator, routine clinical practices.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.
Study: NCT04764773

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04110678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NeuroEPO
Description: NeuroEPO \[CIMAB S.A, Havana, Cuba\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NeuroEPO
Description: NeuroEPO \[CIMAB S.A, Havana, Cuba\]
Study: NCT00395733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentate dimeglumine (Magnevist, BAY86-4882)
Description: Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentate dimeglumine (Magnevist, BAY86-4882)
Description: Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
Study: NCT01495195

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose
Study: NCT03509285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Placebo
Description: 100 mg lactose tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Placebo
Description: 100 mg lactose tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cenobamate placebo
Description: Sugar pill manufactured to mimic cenobamate 100 mg tablet
Study: NCT02534896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment I
Description: Sunpharma1505 and Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment II
Description: Sunpharma1505 and Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment III
Description: Reference1505 and Placebo
Study: NCT03509285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cenobamate placebo
Description: Sugar pill manufactured to mimic cenobamate 100 mg tablet
Study: NCT01411618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: free alcohol essential oil mouthwash
Description: All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: free alcohol essential oil mouthwash
Description: All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
Study: NCT01931618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online screening and feedback
Description: An online single session screening procedure including individualized normative feedback.
Study: NCT03509285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cenobamate placebo
Description: Sugar pill manufactured to mimic cenobamate 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate placebo
Description: Sugar pill manufactured to mimic cenobamate 100 mg tablet
Study: NCT01575470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mononuclear cells
Description: bone marrow harvest (5ml/kg of body weight) performed within 36 hours of injury, followed by single intravenous infusion of bone marrow mononuclear cells.
Study: NCT00711646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Study: NCT03728738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Head of Bed Positioning
Description: The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation
Study: NCT01931618

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online screening and feedback
Description: An online single session screening procedure including individualized normative feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online booklet.
Description: An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online multi session follow-up
Description: An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group).
Study: NCT02826278

Intervention type: OTHER
Intervention: External genitalia measurements in female newborns
Study: NCT00881257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRST Peripheral Catheter System
Description: Treatment to dilate stenoses and reduce plaque in treated vessels
Study: NCT01117948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Description: Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
Study: NCT03728738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head of Bed Positioning
Description: The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation
Study: NCT01117948

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
Study: NCT00233792

Intervention type: DEVICE
Group type: OTHER
Intervention: sirolimus coated Bx VELOCITY stent - fast release

Intervention type: DEVICE
Group type: OTHER
Intervention: sirolimus coated Bx VELOCITY stent - slow release
Study: NCT01835340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug: Propofol Anesthesia Patients will undergo propofol anesthesia.
Study: NCT04206046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anaesthesia
Description: Patients will receive a spinal anaesthetic

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: patients will receive a general anaesthetic and a femoral nerve block
Study: NCT02492464

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red yeast rice
Description: 1 capsule to be taken before to sleep, each day, for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04667988

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: JAK expression
Description: JAK2 assessment in blood by PCR

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: JAK expression
Description: JAK2 assessment in blood by PCR
Study: NCT02454543

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical prostatectomy
Description: Study participants randomized in the intervention arm receive best systemic therapy in addition to radical prostatectomy with extended lymphadenectomy. It is not crucial whether the radical prostatectomy is performed open or robot-assisted.

Intervention type: DRUG
Group type: OTHER
Intervention: Best systemic therapy
Description: For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.~The selection of best systemic therapy is up to the judgment of the treating urologist.
Study: NCT02540135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorescein
Description: fluorescein and conventional neuro-navigation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intraoperative MRI
Description: conventional neuro-navigation and iMRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative MRI
Description: conventional neuro-navigation and iMRI
Study: NCT02245854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exacto™
Description: Cold snare polypectomy
Study: NCT03991949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Formula fed Ad libitum
Study: NCT03509285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: 0.5 mg and 1.0 mg alprazolam tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: 0.5 mg and 1.0 mg alprazolam tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: 0.5 mg and 1.0 mg alprazolam tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: 100 mg tablet
Study: NCT03396588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: 1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
Study: NCT06024343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MPD Exposure, Repair or Reconstruction
Description: During laparoscopic or robotic pancreatic tumor enucleation, if the main pancreatic duct (MPD) is injured due to its proximity or encasement by the tumor, MPD manipulation is performed. MPD manipulation is categorized into three scenarios: exposed but not injured; simple suture repair (using 5-0/6-0 PROLENE polypropylene suture); and suture repair/reconstruction following stent insertion. Using the F6 ventricular drainage catheter with 1-2 side holes trimmed as the stent, typically requiring 10 cm for passage through the duodenal papilla and 3-4 cm if not passing through. Following stent placement, intermittent suturing reconstructs the MPD, with one stitch securing the stent by passing through both the stent side wall and the MPD.
Study: NCT03340506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: dabrafenib is available in capsules (50mg and 75mg) taken twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: dabrafenib is available in capsules (50mg and 75mg) taken twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: trametinib is available in tablets (0.5mg, 2mg dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: trametinib is available in tablets (0.5mg, 2mg dose)
Study: NCT02543385

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S Ketamine
Description: S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S Ketamine
Description: S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
Study: NCT03489083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training was performed three times per week for twelve weeks. Supervised (by qualified sport and exercise scientists) exercise was performed in a gym on three non-consecutive days of the week. Each session lasted \~60 min and consisted of a warm up, the resistance exercise training and a cool down. The training programme consisted of a combination of upper and lower body exercises using gym equipments, free weights and body weight as the primary resistance. The twelve weeks of strength training were divided into three mesocycles of four weeks each. The resistance training was performed using two to three sets per exercise at intensities between 12-15 repetition maximum-RM.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Training
Description: Control group performed a placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks. To avoid any significant adaptation, all stretching exercises (for large muscle groups only) were performed at very low intensity without any significant discomfort.
Study: NCT00396370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG strain Connaught
Description: Connaught strain Bacillus Calmette-Guerin (BCG), 8-32 x 10\^5 CFU vaccine for intradermal administration.